The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms
- PMID: 17204312
- DOI: 10.1016/j.ygyno.2006.10.016
The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms
Abstract
Objective: To investigate the lysophosphatidic acid (LPA) receptors expression situation and their biological significance in human ovarian cancer cell lines and in human epithelial ovarian neoplasms.
Methods: The reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were employed to measure the expression levels of LPA(1), LPA(2) and LPA(3) mRNA, LPA(2) and LPA(3) protein expression in cultured human ovarian cancer cell lines (3AO, SKOV3 and OVCAR3) and in human epithelial ovarian neoplasms. The immunocytochemical method was used to detect LPA(2) and LPA(3) protein expression in cultured human ovarian cancer cell lines.
Results: RT-PCR revealed that all ovarian cancer cell lines expressed LPA(1), LPA(2) and LPA(3) mRNA. The positive rates (100%; 86.4%; 88.2%) of LPA(1) mRNA in normal ovarian tissue, benign tumor and ovarian cancer were no significant difference (p>0.05). The expression level of LPA(1) mRNA was significantly higher in normal ovarian tissue compared with that in benign tumor and in ovarian cancer tissue (p<0.01). LPA(1) expression level was no significant difference in both benign tumor and ovarian cancer tissue (p>0.05). LPA(2) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01); LPA(2) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05). LPA(3) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01), LPA(3) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05). LPA(1) mRNA expression level was significantly decreased compared with that of LPA(2) and LPA(3) in ovarian cancer (p<0.01); Western blotting clearly revealed that all ovarian cancer cell lines showed LPA(2) and LPA(3) protein. The positive rates and expression level of LPA(2) and LPA(3) protein were significantly increased in ovarian cancer (92.6%; 92.6%) compared with that in benign tumor (45.5%; 45.5%) and that in normal ovarian tissue (43.8%; 43.8%) (p<0.01); LPA(2) and LPA(3) protein-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05). Correlation of clinicopathological parameters showed that LPA receptors mRNA and protein expression were associated with FIGO stage and histological grade, except pathologic types and age. The mRNA and protein expression of LPA(2) and LPA(3) in stages III and IV was significantly higher than that in stages I and II epithelial ovarian cancer (p<0.05). The mRNA and protein expression of pathologic grade G(3) was significantly higher compared with grade G(1) (p<0.05).
Conclusion: LPA(1), LPA(2) and LPA(3) mRNA and protein expressed widely in human epithelial ovarian neoplasms. LPA(2) and LPA(3) may be involved in the development and progression of human ovarian cancer. There was a significant correlation between LPA(2), LPA(3) and invasion and metastasis of epithelial ovarian cancer. LPA(2) and LPA(3) may be a prognostic indicator in patients with epithelial ovarian cancer.
Similar articles
-
[Expression of lysophosphatidic acid receptor in human ovarian cancer cell lines 3AO, SKOV3, OVCAR3 and its significance].Di Yi Jun Yi Da Xue Xue Bao. 2005 Nov;25(11):1422-4, 1431. Di Yi Jun Yi Da Xue Xue Bao. 2005. PMID: 16305971 Chinese.
-
Expression and localization of aquaporin-5 in the epithelial ovarian tumors.Gynecol Oncol. 2006 Feb;100(2):294-9. doi: 10.1016/j.ygyno.2005.08.054. Epub 2005 Oct 20. Gynecol Oncol. 2006. PMID: 16242760
-
[Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].Ai Zheng. 2004 Oct;23(10):1194-8. Ai Zheng. 2004. PMID: 15473934 Chinese.
-
[Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].Orv Hetil. 2009 Jun 14;150(24):1109-18. doi: 10.1556/oh.2009.28631. Orv Hetil. 2009. PMID: 19739275 Review. Hungarian.
-
The Role of Lysophosphatidic Acid Receptors in Ovarian Cancer: A Minireview.Crit Rev Eukaryot Gene Expr. 2020;30(3):265-272. doi: 10.1615/CritRevEukaryotGeneExpr.2020031091. Crit Rev Eukaryot Gene Expr. 2020. PMID: 32749113 Review.
Cited by
-
Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.Tumour Biol. 2011 Apr;32(2):311-6. doi: 10.1007/s13277-010-0123-8. Tumour Biol. 2011. PMID: 21061112
-
Lysophosphatidic acid (LPA) signaling in human and ruminant reproductive tract.Mediators Inflamm. 2014;2014:649702. doi: 10.1155/2014/649702. Epub 2014 Mar 12. Mediators Inflamm. 2014. PMID: 24744506 Free PMC article. Review.
-
Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways.J Oncol. 2019 Sep 17;2019:7547469. doi: 10.1155/2019/7547469. eCollection 2019. J Oncol. 2019. PMID: 31636669 Free PMC article.
-
An Insight into GPCR and G-Proteins as Cancer Drivers.Cells. 2021 Nov 24;10(12):3288. doi: 10.3390/cells10123288. Cells. 2021. PMID: 34943797 Free PMC article. Review.
-
Expressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma.Int J Clin Exp Med. 2015 Oct 15;8(10):17880-90. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26770382 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous